个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共21条记录   Active Surveillance for Prostate Cancer: Progress and Promise [作者：Cooperberg, MR; Carroll, PR; Klotz, L,期刊：Journal of clinical oncology, 页码：3669-3676 , 文章类型： Review，,卷期：2011年29-27] Widespread prostate-specific antigen (PSA) -based screening and aggressive treatment of prostate cancer have reduced mortality rates substantially, but both remain controversial in large part because of high rates of ove... Common Gene Rearrangements in Prostate Cancer [作者：Rubin, MA; Maher, CA; Chinnaiyan, AM,期刊：Journal of clinical oncology, 页码：3659-3668 , 文章类型： Review，,卷期：2011年29-27] Prostate cancer is a common heterogeneous disease, and most patients diagnosed in the post prostate-specific antigen (PSA) era present with clinically localized disease, the majority of which do well regardless of treatm... Analysis of Prognostic Factors of Comprehensive Geriatric Assessment and Development of a Clinical Scoring System in Elderly Asian Patients With Cancer [作者：Kanesvaran, R; Li, HH; Koo, KN; Poon, D,期刊：Journal of clinical oncology, 页码：3620-3627 , 文章类型： Article，,卷期：2011年29-27] Purpose To determine the impact of each comprehensive geriatric assessment (CGA) domain on overall survival (OS) and develop a prognostic scoring system for elderly patients with cancer. Patients and Methods A retrospect... Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study [作者：Caillet, P; Canoui-Poitrine, F; Vouriot, J; Berle, M; Reinald, N; Krypciak, S; Bastuji-Garin, S; Culine, S; Paillaud, E,期刊：Journal of clinical oncology, 页码：3636-3642 , 文章类型： Article，,卷期：2011年29-27] Purpose To identify Comprehensive Geriatric Assessment (CGA) components independently associated with changes in planned cancer treatment. Patients and Methods We prospectively included 375 consecutive elderly patients w... Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically [作者：Ryan, CJ; Tindall, DJ,期刊：Journal of clinical oncology, 页码：3651-3658 , 文章类型： Review，,卷期：2011年29-27] Discoveries over the past decade suggest that castration-resistant prostate cancer (CRPC) is sensitive, but not resistant to, further manipulation of the androgen-androgen receptor (AR) axis. Several new therapies that t... Can We Predict Who's at Risk for Developing Bone Metastases in Breast Cancer? [作者：Korde, LA; Gralow, JR,期刊：Journal of clinical oncology, 页码：3600-3604 , 文章类型： Editorial Material，,卷期：2011年29-27] Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14 [作者：Lipton, A; Chapman, JAW; Demers, L; Shepherd, LE; Han, L; Wilson, CF; Pritchard, KI; Leitzel, KE; Ali, SM; Pollak, M,期刊：Journal of clinical oncology, 页码：3605-3610 , 文章类型： Article，,卷期：2011年29-27] Purpose We investigated the association of bone-only relapse with a pretreatment marker of bone resorption: serum beta C-terminal telopeptide (B-CTx) of type I collagen. Methods Pretreatment serum B-CTx concentrations we... Emerging Therapies to Prevent Skeletal Morbidity in Men With Prostate Cancer [作者：Saylor, PJ; Lee, RJ; Smith, MR,期刊：Journal of clinical oncology, 页码：3705-3714 , 文章类型： Review，,卷期：2011年29-27] Skeletal morbidity is a prominent burden to men with advanced prostate cancer throughout the natural history of the disease. Bone metastases can cause pain and greatly elevate the risk for fractures and other structural ... End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice [作者：Scher, HI; Morris, MJ; Basch, E; Heller, G,期刊：Journal of clinical oncology, 页码：3695-3704 , 文章类型： Review，,卷期：2011年29-27] New therapeutic approaches for castration-resistant prostate cancer (CRPC) introduce new treatment dilemmas: how best to sequence these options to maximally benefit patients, what tests to perform before and after treatm... Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial [作者：Pignata, S; Scambia, G; Ferrandina, G; Savarese, A; Sorio, R; Breda, E; Gebbia, V; Musso, P; Frigerio, L; Del Medico, P; Lombardi, AV; Febbraro, A; Scollo, P; Ferro, A; Tamberi, S; Brandes, A; Ravaioli, A; Valerio, MR; Aitini, E; Natale, D; Scaltriti, L; Greggi, S; Pisano, C; Lorusso, D; Salutari, V; Legge, F; Di Maio, M; Morabito, A; Gallo, C; Perrone, F,期刊：Journal of clinical oncology, 页码：3628-3635 , 文章类型： Article，,卷期：2011年29-27] Purpose Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested w... Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer [作者：Seruga, B; Tannock, IF,期刊：Journal of clinical oncology, 页码：3686-3694 , 文章类型： Review，,卷期：2011年29-27] Most men with metastatic prostate cancer respond to various types of androgen ablation but progress to castration-resistant disease. The TAX 327 and Southwest Oncology Group (SWOG) 99-16 clinical trials established docet... Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches [作者：Cha, E; Fong, L,期刊：Journal of clinical oncology, 页码：3677-3685 , 文章类型： Review，,卷期：2011年29-27] Although prostate cancer was not historically considered to be a particularly immune-responsive cancer, recent clinical trials have demonstrated that immunotherapy for prostate cancer can lead to improvements in overall ... Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma [作者：Chiocca, EA; Aguilar, LK; Bell, SD; Kaur, B; Hardcastle, J; Cavaliere, R; McGregor, J; Lo, S; Ray-Chaudhuri, A; Chakravarti, A; Grecula, J; Newton, H; Harris, KS; Grossman, RG; Trask, TW; Baskin, DS; Monterroso, C; Manzanera, AG; Aguilar-Cordova, E; New, PZ,期刊：Journal of clinical oncology, 页码：3611-3619 , 文章类型： Article，,卷期：2011年29-27] Purpose Despite aggressive therapies, median survival for malignant gliomas is less than 15 months. Patients with unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) fare worse, presumably because of temozolomid... Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C [作者：Huang, YT; Jen, CL; Yang, HI; Lee, MH; Su, J; Lu, SN; Iloeje, UH; Chen, CJ,期刊：Journal of clinical oncology, 页码：3643-3650 , 文章类型： Article，,卷期：2011年29-27] Purpose Both hepatitis B (HBV) and C viruses (HCV) are causes of hepatocellular carcinoma (HCC), but lifetime risk and sex difference remain unclear. This study aimed to assess the lifetime risk and sex difference of HCC... Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression (vol 26, pg 3324, 2008) [作者：Anders,期刊：Journal of clinical oncology, 页码：3721-3721 , 文章类型： Correction，,卷期：2011年29-27] Prediction of Response to Targeted Therapies in Lung Cancer Using Dynamic Imaging: Still Far From Clinical Implementation [作者：Quintela-Fandino, M; Colomer, R,期刊：Journal of clinical oncology, 页码：3716-3718 , 文章类型： Letter，,卷期：2011年29-27]